PFBT
CAPR icon

Parkside Financial Bank & Trust’s Capricor Therapeutics CAPR Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,020
Closed -$145K – 2702
2025
Q4 		$145K Buy
5,020
+20
+0.4% +$261 0.01% 547
2025
Q3 		$36K Buy
+5,000
New +$36.8K ﹤0.01% 1044
2025
Q2 		– Sell
-40
Closed -$380 – 2774
2025
Q1 		$380 Buy
+40
New +$555 ﹤0.01% 2565

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Parkside Financial Bank & Trust's CAPR Position: Q1 2026 in Review

Parkside Financial Bank & Trust sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 5,020 shares — an estimated $145K sold.

Parkside Financial Bank & Trust first reported a position in CAPR in Q1 2025 and held it in 3 quarters. The position peaked at $145K in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Parkside Financial Bank & Trust reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 5,020 Capricor Therapeutics shares in Q1 2026, an estimated $145K.
  • Parkside Financial Bank & Trust first reported a position in Capricor Therapeutics in Q1 2025 and held it in 3 quarters.
  • Parkside Financial Bank & Trust's Capricor Therapeutics position peaked at $145K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.